Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: guidelinestudy, GLP
Cross-reference
Reason / purpose for cross-reference:
reference to same study

Data source

Reference
Reference Type:
publication
Title:
Unnamed
Year:
2003

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
Deviations:
yes
Remarks:
a 14-day recovery period : control and high dose animals
Principles of method if other than guideline:
Guideline for the 28-day repeated dose toxicity test in mammalian species (Chemical Substances Control Law of Japan)
GLP compliance:
yes
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
hydrazine monohydrate
Cas Number:
7803-57-8
Molecular formula:
H4N2*H2O
IUPAC Name:
hydrazine monohydrate
Constituent 2
Reference substance name:
hydrazine hydrate
IUPAC Name:
hydrazine hydrate
Details on test material:
IUCLID4 Test substance: other TS: hydrazine monohydrate, purity: 100.15 %

Test animals

Species:
rat
Strain:
other: Crj: CD (SD)IGS
Sex:
male/female
Details on test animals or test system and environmental conditions:
as required by guideline

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Details on oral exposure:
After the 28 day treatment period a 14-day recovery period is reported for the control and the highest test group.
Analytical verification of doses or concentrations:
not specified
Details on analytical verification of doses or concentrations:
no given
Duration of treatment / exposure:
28 d
Frequency of treatment:
daily
Doses / concentrations
Remarks:
Doses / Concentrations:
0, 1, 3, 10, 30 mg/kg bw/day (corresponding to 0, 0.64-19.2 mg/kg bw/d hydrazine)
Basis:

No. of animals per sex per dose:
5 males and 5 females/per dose group including control animals
Control animals:
yes, concurrent vehicle
Details on study design:
Post-exposure period: 14 d
Positive control:
no

Examinations

Observations and examinations performed and frequency:
clinical signs, food comsumption, body weight, hematology, blood chemistry, urinalysis
Sacrifice and pathology:
all animals were autopsied
rel and absolute organ weight, gross findings, histopathological findings
Other examinations:
no further information
Statistics:
Appropriate statistical methods were used: eg. non-parametric analysis (no further information)

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Mortality:
mortality observed, treatment-related
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Food efficiency:
effects observed, treatment-related
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
effects observed, treatment-related
Clinical biochemistry findings:
effects observed, treatment-related
Urinalysis findings:
no effects observed
Behaviour (functional findings):
not examined
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Gross pathological findings:
effects observed, treatment-related
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Histopathological findings: neoplastic:
no effects observed
Details on results:
see section remarks on results

Effect levels

Dose descriptor:
NOAEL
Effect level:
3 mg/kg bw/day (actual dose received)
Sex:
male/female
Basis for effect level:
other: (corresponding to 1.92 mg/kg bw/d) based on adverse effects from 10 mg/kg bw/d onwards including changes in hematology, blood chemistry and changes in liver, spleen and kidneys

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

CLINICAL OBSERVATIONS AND FREQUENCY:
-Mortality:
No deaths were observed
-Clinical signs:
30 mg/kg bw/d:
males+females: wasting, piloerection, salivation;
females: dirty nasal discharge
30 mg/kg bw/d (males and females):
-Body weight gain, food consumption, food efficiency suppressed, reversable during recovery

--HEMATOLOGY (significant changes)
-------males, 30 mg/kg bw:
significant decrease:
HCT: 38.0 % vs 44.8 % of control; recovery in 14 d
HGB: 11.9 g/dL vs 15.1 g/dL of control; recovery in 14 d
MCV: 51.8 µm3 vs 57.3 µm3 of control; recovery in 14 d
MCH: 16.2 pg vs 19.6 pg of control; recovery in 14 d
MCHC: 31.3 % vs 34.2 % of control
PT: 14.4 sec vs 17.5 sec of control; recovery in 14 d
APTT: 19.6 sec 24.2 sec of control; recovery in 14 d
significant increase but recovery in 14 d:
Reticulocytes: 6.2 % vs 2.8 % of control;
Methemoglobin: 0.99 % vs 0.75 % of control;
PLT count: 1786 10³/mm3 vs 1304 10³/mm3 of control
------females,
---from 10 mg/kg bw onwards significant decrease but recovery in 14 d
HCT: 40.5 %, 34.7 % % vs 43.6 % of control;
HGB: 14.0 g/dL, 10.6 g/dL vs 15.3 g/dL of control;
MCH: 18.7 pg, 16.6 pg vs 19.7 pg of control;
---30 mg/kg bw significant dercrease
RBC: 6.43x10[exp6]/mm³ vs 7.77 x10[exp6]/mm³of control; recovery in 14 d
MCHC: 30.7 % vs 35.1 % of control
---30 mg/kg bw significant increase but recovery in 14 d:
Reticulocytes: 9.2 % vs 2.2 % of control;
Methemoglobin: 1.0 % vs 0.52 % of control

--CLINICAL CHEMISTRY (significant changes):
------Male, 30 mg/kg bw but recovery in 14 d
Glucose (mg/dL): 100 vs. 140 of control
BUN (mg/dL): 22.5 vs. 13.7 of control
Tbilirubin (mg/dL): 0.12 vs. 0.04 of control
Albumin (g/dL): 3.86 vs. 3.60 of control
A/G ratio : 2.37 vs. 1.80 of control
Chloride (mmol/L): 104.6 vs. 108 of control
Iphosphate (mg/dL): 9.54 vs. 8.05 of control
AST (U/L): 51 vs. 77 of control
ALT (U/L): 17 vs. 32 of control
------female, at 10 mg/kg bw but recovery in 14 d
AST (U/L): 62 vs. 73 of control
ALT (U/L): 17 vs. 25 of control
------female, 30 mg/kg bw but recovery in 14 d
Glucose (mg/dL): 83 vs. 114 of control
Tbilirubin (mg/dL): 0.11 vs. 0.03 of control
A/G ratio : 2.42 vs. 1.77 of control
Chloride (mmol/L): 102 vs. 108 of control
Calcium (mg/dL): 10.49 vs. 9.74 of control
Iphosphate (mg/dL): 9.81 vs. 7.56 of control

----------GROSS AND HISTOPATHOLOGY
---The absolute weights of
the kidneys were increased or tended to be increased in both sexes of the 10 and 30 mg/kg bw groups; elevation of liver weights in females of the 10 and 30 mg/kg bw groups and of spleen weights in 30 mg /kg bw females was apparent.
---Relative weights of
the liver and kidneys were higher or tended to be higher in both sexes of the 10 and 30 mg/kg bw groups than in controls. liver males: 3.01%,3.5% versus 2.7%, recovery in 14 d liver females: 3.2%,3.9% versus 2.7%, after 14d: 3.2% versus 2.7% kidneys males: 0.84%,1.04 versus 0.76%, recovery in 14 d kidneys females: 0.86%, 0.96% versus 0.79%, after 14 d: 0.85% versus 0.75%
---Macroscopically,
pale colored livers were observed in both sexes of the 30 mg/kg bw group.
---Histopathologically,
fatty change of the hepathocytes was observed in males of the 10 and 30 mg/kg bw groups and in females of all groups including the controls. Pigmentation of the spleen was observed in both sexes of the 30 mg/kg bw group. A higher degree of extramedullary hematopoiesis than normal was observed in both sexes of the 30 mg/kg bw group and in males of the 10 mg/kg bw group.

Applicant's summary and conclusion

Executive summary:

In a subacute toxicity study according to OECD TG 407 hydrazine monohydrate was administered to male and female Crj:CD(SD)IGS rats by gavage at dose levels of 0, 1, 3, 10, 30 mg/kg bw/day diluted in water. Additionally, the control group and the highest dose group were observed during a 14-day recovery period (MHLW 2003). Based on adverse effects from 10 mg/kg bw/d onwards including changes in hematology, blood chemistry and changes in liver, spleen and kidneys the NOAEL is 3 mg/kg bw/day for male and female rats.